AC Immune SA Shareholders’ Equity Growth & History (ACIU)
AC Immune SA's shareholders’ equity was CHF44.9M for fiscal 2025.
View full AC Immune SA company overviewAC Immune SA annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | CHF44.9M | −CHF67.4M | −60.02% |
| 2024 | 2024-12-31 | CHF112.3M | −CHF48.4M | −30.11% |
| 2023 | 2023-12-31 | CHF160.6M | −CHF8.3M | −4.94% |
| 2022 | 2022-12-31 | CHF169.0M | −CHF63.0M | −27.15% |
| 2021 | 2021-12-31 | CHF232.0M | CHF16.5M | +7.66% |
| 2020 | 2020-12-31 | CHF215.5M | −CHF57.0M | −20.91% |
| 2019 | 2019-12-31 | CHF272.4M | CHF94.8M | +53.38% |
| 2018 | 2018-12-31 | CHF177.6M | CHF60.8M | +52.02% |
| 2017 | 2017-12-31 | CHF116.8M | −CHF25.5M | −17.94% |
| 2016 | 2016-12-31 | CHF142.4M | CHF71.3M | +100.41% |
| 2015 | 2015-12-31 | CHF71.0M | — | — |
AC Immune SA quarterly shareholders’ equity
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | CHF35.2M | −CHF39.6M | −52.95% |
| Q1 2026 | 2026-03-31 | CHF31.5M | — | — |
| Q4 2025 | 2025-12-31 | CHF44.9M | −CHF67.4M | −60.02% |
| Q3 2025 | 2025-09-30 | CHF62.4M | — | — |
| Q2 2025 | 2025-06-30 | CHF74.7M | −CHF48.7M | −39.44% |
| Q4 2024 | 2024-12-31 | CHF112.3M | −CHF48.4M | −30.11% |
| Q2 2024 | 2024-06-30 | CHF123.4M | −CHF15.9M | −11.41% |
| Q4 2023 | 2023-12-31 | CHF160.6M | −CHF8.3M | −4.94% |
| Q2 2023 | 2023-06-30 | CHF139.3M | — | — |
| Q4 2022 | 2022-12-31 | CHF169.0M | −CHF63.0M | −27.15% |
| Q3 2022 | 2022-09-30 | CHF190.1M | — | — |
| Q4 2021 | 2021-12-31 | CHF232.0M | CHF16.5M | +7.66% |
| Q4 2020 | 2020-12-31 | CHF215.5M | −CHF57.0M | −20.91% |
| Q4 2019 | 2019-12-31 | CHF272.4M | CHF94.8M | +53.38% |
| Q4 2018 | 2018-12-31 | CHF177.6M | CHF60.8M | +52.02% |
| Q4 2017 | 2017-12-31 | CHF116.8M | — | — |
AC Immune SA shareholders’ equity trends
Over the last five fiscal years, AC Immune SA's shareholders’ equity decreased from CHF215.5M to CHF44.9M, a change of −CHF170.6M. The latest reported quarter, Q2 2026, shows CHF35.2M.
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AC Immune SA source filings ↗